Payment overview · 2025
General Payments
$529.38
24 reported records · 9 companies
Healthcare provider profile · identity verified
Erik N. Watson, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ATTLEBORO, MA · NPI 1477577799
Verified facts
What the public records show
CMS Open Payments records show Erik N. Watson, M.D. received $529.38 in general payments during 2025 across 24 reported records.
Novo Nordisk Inc accounted for 39.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $210.24 | 39.7% | 9 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $58.03 | 11.0% | 3 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $56.85 | 10.7% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $48.20 | 9.1% | 2 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $40.85 | 7.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $40.00 | 7.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.37 | 6.9% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $19.98 | 3.8% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $18.86 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $529.38 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $210.24 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $63.54 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $58.03 | 3 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $56.85 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $48.20 | 2 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $40.85 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $21.13 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.50 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $16.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 28 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 522 | 134 |
| Losartan Potassium | Losartan Potassium | 387 | 103 |
| Amlodipine Besylate | Amlodipine Besylate | 357 | 104 |
| Levothyroxine Sodium | Levothyroxine Sodium | 321 | 84 |
| Metoprolol Succinate | Metoprolol Succinate | 300 | 82 |
| Lisinopril | Lisinopril | 287 | 82 |
| Omeprazole | Omeprazole | 287 | 73 |
| Gabapentin | Gabapentin | 229 | 57 |
| Lorazepam | Lorazepam | 200 | 32 |
| Tramadol Hcl | Tramadol Hcl | 181 | 39 |
| Furosemide | Furosemide | 166 | 36 |
| Alendronate Sodium | Alendronate Sodium | 154 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 146 | 48 |
| Metformin Hcl Er | Metformin Hcl | 143 | 37 |
| Simvastatin | Simvastatin | 141 | 37 |
| Alprazolam | Alprazolam | 132 | 23 |
| Eliquis | Apixaban | 128 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 122 | 35 |
| Potassium Chloride | Potassium Chloride | 117 | 29 |
| Trazodone Hcl | Trazodone Hcl | 114 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 110 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 110 | 17 |
| Atenolol | Atenolol | 102 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 101 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 101 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 99 | 24 |
| Sertraline Hcl | Sertraline Hcl | 99 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 96 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 88 | 18 |
| Metformin Hcl | Metformin Hcl | 84 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 18 |
| Mirtazapine | Mirtazapine | 72 | 13 |
| Meloxicam | Meloxicam | 71 | 14 |
| Clonazepam | Clonazepam | 70 | 13 |
| Warfarin Sodium | Warfarin Sodium | 69 | 11 |
| Carvedilol | Carvedilol | 67 | 14 |
| Prednisone | Prednisone | 66 | 34 |
| Ibuprofen | Ibuprofen | 64 | 15 |
| Glipizide Er | Glipizide | 62 | 20 |
| Allopurinol | Allopurinol | 60 | 18 |
| Diazepam | Diazepam | 54 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 50 | suppressed |
| Azithromycin | Azithromycin | 45 | 34 |
| Felodipine Er | Felodipine | 44 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 38 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 36 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 36 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 34 | 26 |
| Glimepiride | Glimepiride | 33 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 33 | suppressed |
| Bumetanide | Bumetanide | 32 | suppressed |
| Celecoxib | Celecoxib | 32 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 23 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 23 |
| Jardiance | Empagliflozin | 28 | 11 |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Hydrocortisone | Hydrocortisone | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Methadone Hcl | Methadone Hcl | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Klor-Con M20 | Potassium Chloride | 24 | suppressed |
| Nystatin | Nystatin | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Ozempic | Semaglutide | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 11 |
| Torsemide | Torsemide | 21 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 11 |
| Tradjenta | Linagliptin | 20 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 19 | suppressed |
| Fentanyl | Fentanyl | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 14 |
| Famotidine | Famotidine | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 11 | suppressed |
| Levoxyl | Levothyroxine Sodium | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $529.38 · 24 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, BREZTRI, CeQur Simplicity, DUPIXENT, FREESTYLE LIBRE 3, JARDIANCE, JATENZO, MOUNJARO, Ozempic, Rybelsus, TRELEGY ELLIPTA, XYOSTED | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error